Document is current
Any future updates will be listed below
-
Authors
Dhakal, Binod
D’Souza, Anita
Hamadani, Mehdi
Arce-Lara, Carlos
Schroeder, Katrina
Chhabra, Saurabh
Shah, Nirav N.
Gauger, Katelyn
Keaton, Taylor
Pasquini, Marcelo
Hari, Parameswaran
-
Funding
Funding for this research was provided by:
Takeda Pharmaceutical Company Limited | Takeda Oncology
- License Information
-
More Information
Article History
Received: 25 March 2019
Accepted: 22 May 2019
First Online: 29 July 2019
Conflict of interest
: B.D. has served on the advisory board for Takeda and Amgen. P.H. has received grant support and consulting honoraria from Takeda. A.D.—institutional funding: Amgen, Celgene, Merck, Prothena, Takeda; Consultancy: Prothena; Advisory board- Pfizer. M.H. reports Research Support/Funding: Takeda Pharmaceutical Company; Otsuka Pharmaceutical; Spectrum Pharmaceuticals; Astellas Pharma. Consultancy: MedImmune LLC; Janssen R &D; Incyte Corporation; ADC Therapeutics; Cellerant Therapeutics; Celgene Corporation; Pharmacyclics & DOVA Oncology. Speaker’s Bureau: Celgene Corporation (Inactive); Sanofi Genzyme. N.N.S. reports research funding from Lentigen, A miltenyi biotech company. He has served on the advisory boards for Kite, Juno, and Cellectar. The remaining authors declare that they have no conflict of interest.
